Home LiteratureArticle Details
PMID: 18827027 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1.

Tan L, Sarkis PT, Wang T, Tian C, Yu XF

Abstract

Human cytidine deaminase apolipoprotein B mRNA-editing catalytic polypeptide-like 3 (APOBEC3) proteins have been classified as either Z1- or Z2-type cytidine deaminases on the basis of phylogenetic analysis of their catalytic domains. Despite the identification of a number of Z1-type domain-containing cytidine deaminases, only one copy of Z2-type cytidine deaminase has been detected in each of the mammalian species evaluated thus far. Z1-type human APOBEC3 proteins are known to exhibit broad activities against diverse retroelements. However, the potential role of the only human Z2-type cytidine deaminase, APOBEC3H (A3H), in the restriction of retroelements has not yet been fully characterized. Here, we demonstrate that human A3H is a potent inhibitor of non-LTR LINE-1 transposition. Interestingly, it was also as efficient as A3G in inhibiting Alu retrotransposition, despite its poor association with Alu RNA. We have further demonstrated, for the first time, that human APOBEC3DE is also a potent inhibitor of Alu retrotransposition. Variants of A3H have divergent antiviral activities against HIV-1-Vif-deficient viruses. Unlike the anti-HIV-1 cytidine deaminases A3G and A3F, A3H is moderately regulated by interferons. These observations suggest that human Z2-type cytidine deaminase A3H variants have varying intrinsic abilities to restrict retroelements and that various APOBEC3 proteins may have evolved distinct inhibitory mechanisms against retroelements.

MeSH Terms
Alu Elements/drug effects,genetics,physiology Aminohydrolases Cell Line Cytosine Deaminase/pharmacology HIV-1/drug effects Humans Isoenzymes Long Interspersed Nucleotide Elements/drug effects,physiology Retroelements/drug effects,physiology
Chemicals
Isoenzymes Retroelements APOBEC3H protein, human Aminohydrolases Cytosine Deaminase
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Tan Lindi
Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Sarkis Phuong Thi Nguyen
Wang Tao
Tian Chunjuan
Yu Xiao-Fang
References (83)
83 references, click to expand
  1. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.
    Genes Dev. 2004 Dec 1;18(23):2861-6 PMID: 15574592
  2. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.
    J Virol. 2007 Dec;81(24):13346-53 PMID: 17928335
  3. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.
    J Virol. 2006 Jun;80(12):5984-91 PMID: 16731937
  4. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.
    PLoS Biol. 2004 Sep;2(9):E275 PMID: 15269786
  5. Comment on "Inhibition of hepatitis B virus replication by APOBEC3G".
    Science. 2004 Sep 3;305(5689):1403; author reply 1403 PMID: 15353783
  6. LINE-mediated retrotransposition of marked Alu sequences.
    Nat Genet. 2003 Sep;35(1):41-8 PMID: 12897783
  7. Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses.
    Nucleic Acids Res. 2006;34(5):1522-31 PMID: 16537839
  8. APOBEC3G targets specific virus species.
    J Virol. 2004 Aug;78(15):8238-44 PMID: 15254195
  9. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis.
    Cell Cycle. 2005 Sep;4(9):1281-5 PMID: 16082223
  10. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
    Science. 2003 Nov 7;302(5647):1056-60 PMID: 14564014
  11. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.
    J Virol. 2005 Sep;79(17):10978-87 PMID: 16103149
  12. Intrinsic immunity: a front-line defense against viral attack.
    Nat Immunol. 2004 Nov;5(11):1109-15 PMID: 15496950
  13. APOBEC3 proteins inhibit human LINE-1 retrotransposition.
    J Biol Chem. 2006 Aug 4;281(31):22161-72 PMID: 16735504
  14. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.
    J Biol Chem. 2004 Dec 17;279(51):53379-86 PMID: 15466872
  15. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.
    J Exp Med. 2006 Jan 23;203(1):41-6 PMID: 16418394
  16. Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
    J Virol. 2006 Dec;80(23):11710-22 PMID: 16971427
  17. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA.
    J Biol Chem. 2007 Apr 20;282(16):11667-75 PMID: 17272283
  18. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    J Virol. 2007 Jul;81(13):7238-48 PMID: 17428847
  19. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G.
    Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11444-9 PMID: 16076960
  20. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast.
    Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9854-9 PMID: 16000409
  21. Determination of L1 retrotransposition kinetics in cultured cells.
    Nucleic Acids Res. 2000 Mar 15;28(6):1418-23 PMID: 10684937
  22. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
    Nature. 2003 Jul 3;424(6944):94-8 PMID: 12808465
  23. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
    Cell. 2003 Jul 11;114(1):21-31 PMID: 12859895
  24. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
    Curr Biol. 2004 Aug 10;14(15):1385-91 PMID: 15296757
  25. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
    J Virol. 2004 Jun;78(11):6073-6 PMID: 15141007
  26. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    J Virol. 2007 Aug;81(15):8201-10 PMID: 17522216
  27. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
    J Virol. 2004 Nov;78(21):11841-52 PMID: 15479826
  28. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
    Nat Struct Mol Biol. 2004 May;11(5):435-42 PMID: 15098018
  29. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.
    Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8780-5 PMID: 16728505
  30. Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus.
    J Biol Chem. 2004 Oct 1;279(40):41744-9 PMID: 15297452
  31. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif.
    Virology. 2005 Sep 1;339(2):281-8 PMID: 15993456
  32. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification.
    PLoS Pathog. 2005 Sep;1(1):e6 PMID: 16201018
  33. Selective inhibition of Alu retrotransposition by APOBEC3G.
    Gene. 2007 Apr 1;390(1-2):199-205 PMID: 17079095
  34. Retrovirus restriction factors.
    Mol Cell. 2004 Dec 22;16(6):849-59 PMID: 15610729
  35. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.
    Genes Dev. 2004 Dec 1;18(23):2867-72 PMID: 15574593
  36. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif.
    Virology. 2006 Jun 5;349(2):290-9 PMID: 16530799
  37. Human cytidine deaminase APOBEC3H restricts HIV-1 replication.
    J Biol Chem. 2008 Apr 25;283(17):11606-14 PMID: 18299330
  38. All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition.
    Nucleic Acids Res. 2007;35(9):2955-64 PMID: 17439959
  39. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex.
    Virology. 2006 Jan 20;344(2):263-6 PMID: 16303161
  40. Hot L1s account for the bulk of retrotransposition in the human population.
    Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5280-5 PMID: 12682288
  41. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition.
    Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15588-93 PMID: 17030807
  42. DNA deamination mediates innate immunity to retroviral infection.
    Cell. 2003 Jun 13;113(6):803-9 PMID: 12809610
  43. Editing at the crossroad of innate and adaptive immunity.
    Science. 2005 Feb 18;307(5712):1061-5 PMID: 15718460
  44. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G.
    FASEB J. 2007 Jan;21(1):217-22 PMID: 17135358
  45. Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association.
    J Virol. 2007 Sep;81(17):9577-83 PMID: 17582006
  46. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family.
    J Virol. 2006 Nov;80(21):10522-33 PMID: 16920826
  47. STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha.
    J Immunol. 2006 Oct 1;177(7):4530-40 PMID: 16982890
  48. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.
    Hepatology. 2006 Jun;43(6):1364-74 PMID: 16729314
  49. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases.
    Mol Biol Evol. 2005 Feb;22(2):367-77 PMID: 15496550
  50. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Nature. 2003 Jul 3;424(6944):99-103 PMID: 12808466
  51. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
    J Virol. 2006 Jan;80(2):875-82 PMID: 16378989
  52. Inhibition of hepatitis B virus replication by APOBEC3G.
    Science. 2004 Mar 19;303(5665):1829 PMID: 15031497
  53. High frequency retrotransposition in cultured mammalian cells.
    Cell. 1996 Nov 29;87(5):917-27 PMID: 8945518
  54. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    J Mol Biol. 2008 Sep 12;381(4):1000-11 PMID: 18619467
  55. Recent insights into HIV-1 Vif.
    Curr Opin Immunol. 2004 Aug;16(4):477-82 PMID: 15245742
  56. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
    Nature. 2005 May 5;435(7038):108-14 PMID: 15829920
  57. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses.
    Nature. 2005 Jan 27;433(7024):430-3 PMID: 15674295
  58. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
    J Virol. 2005 Aug;79(15):9579-87 PMID: 16014920
  59. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    J Virol. 2006 Mar;80(6):3112-5 PMID: 16501124
  60. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H.
    J Virol. 2006 Apr;80(8):3853-62 PMID: 16571802
  61. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.
    Curr Biol. 2006 Mar 7;16(5):480-5 PMID: 16527742
  62. Hypermutation of HIV-1 DNA in the absence of the Vif protein.
    Science. 2003 May 16;300(5622):1112 PMID: 12750511
  63. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
    J Virol. 2006 Sep;80(17):8450-8 PMID: 16912295
  64. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
    Nucleic Acids Res. 2005;33(6):1913-23 PMID: 15809227
  65. A zinc-binding region in Vif binds Cul5 and determines cullin selection.
    J Biol Chem. 2006 Jun 23;281(25):17259-65 PMID: 16636053
  66. Human APOBEC3G incorporation into murine leukemia virus particles.
    Virology. 2005 Jun 20;337(1):175-82 PMID: 15914230
  67. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
    Nat Med. 2003 Nov;9(11):1398-403 PMID: 14528301
  68. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
    Curr Biol. 2003 Nov 11;13(22):2009-13 PMID: 14614829
  69. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.
    EMBO J. 2004 Jun 16;23(12):2451-8 PMID: 15152192
  70. Cell-specific regulation of APOBEC3F by interferons.
    Acta Biochim Biophys Sin (Shanghai). 2007 Apr;39(4):297-304 PMID: 17417686
  71. Cytidine deamination of retroviral DNA by diverse APOBEC proteins.
    Curr Biol. 2004 Aug 10;14(15):1392-6 PMID: 15296758
  72. G to A hypermutation of hepatitis B virus.
    Hepatology. 2005 Mar;41(3):626-33 PMID: 15726649
  73. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.
    J Virol. 2008 Mar;82(6):2652-60 PMID: 18184715
  74. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.
    J Virol. 2007 Jul;81(13):7099-110 PMID: 17428871
  75. Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes.
    Biochem Biophys Res Commun. 2006 Mar 10;341(2):314-9 PMID: 16426578
  76. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Nat Med. 2003 Nov;9(11):1404-7 PMID: 14528300
  77. The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay.
    J Biol Chem. 2004 Oct 15;279(42):43371-3 PMID: 15322092
  78. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism.
    J Biol Chem. 2006 Jun 23;281(25):16837-41 PMID: 16648136
  79. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
    J Biol Chem. 2004 Feb 27;279(9):7792-8 PMID: 14672928
  80. Initial sequencing and analysis of the human genome.
    Nature. 2001 Feb 15;409(6822):860-921 PMID: 11237011
  81. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.
    Nucleic Acids Res. 2004;32(8):2421-9 PMID: 15121899
  82. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo.
    Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8321-6 PMID: 15919829
  83. Retroviral restriction by APOBEC proteins.
    Nat Rev Immunol. 2004 Nov;4(11):868-77 PMID: 15516966
Article Info
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Abbr.
FASEB J
ISSN
1530-6860
Published
2009-01-00
Epub
2008-00-30
Pages
279-87
Language
English
Region
United States
NLM ID
8804484
PMCID
PMC2626612
Subset
IM
Grants
NIAID NIH HHS · R21 AI071769 · United States
NIAID NIH HHS · AI071769 · United States
NIAID NIH HHS · R01 AI062644-05 · United States
NIAID NIH HHS · R56 AI062644 · United States
NIAID NIH HHS · AI062644 · United States
NIAID NIH HHS · R01 AI062644 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com